Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

GAITHERSBURG, Md., Aug. 23 /PRNewswire/ -- MedImmune, Inc. today announced that in a Phase 3 study, motavizumab was shown to reduce hospitalizations due to respiratory syncytial virus (RSV) by 83 percent as compared to placebo (8.3 percent in placebo arm vs. 1.4 percent in motavizumab; p<0.001), as the trial's primary endpoint. In addition, the trial showed a 71-percent reduction in the incidence of RSV-specific lower respiratory infections (LRIs) requiring outpatient management (9.5 percent in placebo group and 2.8 percent in the motavizumab group; p<0.001), which was a secondary endpoint.

Motavizumab is an investigational monoclonal antibody (MAb) being evaluated for its potential to prevent serious disease caused by RSV in high-risk pediatric patients. This Phase 3 trial involved 1,410 full-term infants less than six months of age in two Native American populations. In previous medical studies these populations were shown to have high rates of hospitalization due to RSV.

The randomized (2:1), double-blind study was designed to compare monthly intramuscular injections of motavizumab against placebo. After an interim analysis conducted by an independent data safety monitoring committee, the study was unblinded early due to statistical evidence demonstrating that motavizumab reduced RSV hospitalizations and LRIs requiring outpatient medical management within this population. Kate O'Brien, M.D., associate professor at the Center for American Indian Health, Johns Hopkins Bloomberg School of Public Health, served as the study's principal investigator.

"We are pleased with the results of this study which support the positive results seen in our Phase 3 pivotal trial comparing motavizumab and Synagis(R) (palivizumab) that were previously reported at the Pediatric Academic Societies meeting in May 2007," said Genevieve Losonsky, M.D., vice president, clinical development, infectious disease, MedImmune.

Motavizumab was well tolerated in these
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015  The report on breast cancer therapeutics: ... cancer drugs on the basis of the molecules which ... the inner lining of milk ducts or lobules responsible ... of tumor that can spread to other cells present ... in lobules is referred as lobular carcinoma, while the ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
(Date:9/2/2015)... MONROVIA, Calif. , Sept. 2, 2015 STAAR ... and marketer of implantable lenses and delivery systems for the ... William P. Wall to the Company,s Board. ... Abrams Capital, a Boston -based investment firm, ... member of the Board of Directors, and chair of the ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2William P. Wall Appointed to STAAR Surgical Board of Directors 2
... CEL-SCI Corporation,(Amex: CVM ) announced today that it ... its lead drug Multikine(R) on October 8, 2008.,This dedicated ... for,CEL-SCI,s pivotal Phase III clinical trial for first-line therapy ... for,sale following approval of the drug. The facility, which ...
... 0901 is Being Developed as an Oral Dosage Form ... at Improving Glycemic Control in Adults With Type 2 ... (OTCBB: ORMP.OB), a developer of oral drug delivery,systems, announced ... a GLP1-analog., ORMD 0901 belongs to the Incretin ...
Cached Medicine Technology:CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008 2CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008 3Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform 2
(Date:9/2/2015)... ... September 02, 2015 , ... The CRISPR-Cas9 system introduces double-strand DNA ... Cas9 nuclease with either a chimeric single guide RNA (sgRNA) or two short RNAs ... guide RNA (sgRNA or crRNA) to create a break in the target DNA that ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... healthcare innovation and investment, announced the two leaders who will deliver keynote presentations ... November 3, at the Mandarin Oriental Hotel in Boston. , Larry Renfro, CEO ...
(Date:9/2/2015)... ... 2015 , ... Telehealth represents a growing trend among Blue Cross and Blue ... of more than 12 Blues plan clients. The September 2015 issue of ... growing trend, interviewing executives at Capital Blue Cross, whose telehealth services will launch next ...
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... ambulatory healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing ... “new look” and focus on improving prescriber usability. A leader in health technology, ...
Breaking Medicine News(10 mins):Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 2Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 3Health News:GE Healthcare Webinar Discusses Improvements to CRISPR-Cas9 Gene Editing 4Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 2Health News:AIS Newsletter Focuses on Growing Telehealth Trend Among Blues Plans 3Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2
... Clinic to Automate Three Offices with High Performance DR ... ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics Company,Ltd.) (TSX: IDL), the global leader ... a contract by,Orthopaedic Clinic of Daytona Beach in Florida for four ...
... Blue Cross ... ... California,(Blue Cross) today announced the inclusion of HealthCare Partners Medical,Group and ... preferred provider, effective January 1, 2008., HealthCare Partners serves more ...
... Feb. 4, 2008 Theres new hope for breast ... place. Researchers at the Texas A&M University College of ... the journals Molecular and Cellular Biology and Carcinogenesis indicating ... in Down Syndrome may also contribute to treating this ...
... Forms Alliance With Veterinary News Network, MODESTO, ... in,veterinary hospital captive audience digital signage solutions and ... one of the,most comprehensive client education systems in ... partnering with emebaVet, bringing interesting,and accurate pet health ...
... Feb. 4 George Abercrombie, president and chief,executive ... Atlanta,business leaders today at a Rotary Club of ... presents businesses with challenges unlike those,anticipated with traditional ... too familiar with preparing for potential,disasters such as ...
... 4 In the first study to directly compare ... indicated overall satisfaction with the vaginal ring, researchers report ... publication of the American College of Obstetricians and Gynecologists. ... birth control pills, these products became available in 2002 ...
Cached Medicine News:Health News:Orthopaedic Clinic of Daytona Beach Chooses IDC for Transition to Digital X-ray 2Health News:HealthCare Partners Physicians Join Blue Cross of California 'Power Select HMO' Network 2Health News:Vet medicine researcher examines link between cancer, Down syndrome 2Health News:emebaVet, LLC Client Education System Gets Bigger and Better in 2008 2Health News:emebaVet, LLC Client Education System Gets Bigger and Better in 2008 3Health News:CEO Addresses Georgia Business Leaders About Developing Pandemic and Business Continuity Plans 2Health News:CEO Addresses Georgia Business Leaders About Developing Pandemic and Business Continuity Plans 3Health News:Ringing endorsement: Women prefer contraceptive ring over patch 2
... 525 is an assayed quality control ... of blood gas, electrolyte, metabolite, and ... this control makes it the ideal ... It is available in three (3) ...
Xsera Rapid HIV-1/2 Antibody Controls are unassayed positive and negative quality control materials used for monitoring the performance of qualitative rapid HIV-1 and HIV-2 test kits....
For the qualitative detection of igG antibodies specific to Helicobacter pylori in human serum, plasma and whole blood specimens...
For the qualitative detection of human occult blood in fecal specimens....
Medicine Products: